Urania Therapeutics SAS

https://www.uraniatx.com

Urania Therapeutics is a privately held French biopharmaceutical company specializing in the identification and development of ‘readthrough’ compounds following a structure-based-drug design approach (SBDD). These compounds induce the overcoming of premature stop codons during protein synthesis to allow the production of missing full-length protein. In restoring production of functional protein by targeting the decoding centre of the human ribosome, the aim is to provide new therapeutic options for a vast array of monogenic diseases, such as Duchenne Muscular Dystrophy (DMD) and Cystic Fibrosis (CF), as well as certain cancer subtypes caused by nonsense mutations, a new illustration of precision medicine. Urania Therapeutics’ approach relies on the work and expertise of its scientific founders, world-leading ribosome structure experts Marat Yusupov and Gulnara Yusupova, CNRS research directors at IGBMC (Institute of Genetics and Molecular and Cellular Biology). Headquartered in Strasbourg (France), the company was created in 2015. *

	Start	2015-10-06 established
	Predecessor	IGBMC (Institute of Genetics and Molecular and Cellular Biology – Unistra/INSERM/CNRS, Strasbourg)
	Industry	BIOTECH
	Person	Renaud, Jean-Paul (Urania Therapeutics 201911 CSO + Founder)

	Region	Strasbourg
	Country	France
	Street	15 Rue Neuve
	City	67540 Ostwald
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Urania Therapeutics SAS. (11/6/19). "Press Release: Urania Therapeutics Closes a €3.5M Initial Seed Round". Strasbourg.

		Record changed: 2024-03-30